Durvalumab Consolidation Should Be the Standard Therapy in Stage III EGFR-Mutant NSCLC After Chemoradiation

被引：5
|
作者：
Morgensztern, Daniel [1 ]
Govindan, Ramaswamy [1 ]
机构：
[1] Washington Univ, Div Med Oncol, Dept Med, Sch Med, St Louis, MO 63110 USA
来源：
JOURNAL OF THORACIC ONCOLOGY | 2021年 / 16卷 / 12期
关键词：
CELL LUNG-CANCER; CHECKPOINT INHIBITORS; SURVIVAL;
D O I：
10.1016/j.jtho.2021.07.034
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：1999 / 2001
页数：3
相关论文
共 50 条
  • [41] EGFR tyrosine kinase inhibitors (TKIs) versus durvalumab (durva) following concurrent chemoradiation (CRT) in unresectable EGFR-mutant non-small-cell lung cancer (NSCLC)
    Nassar, Amin
    Adib, Elio
    Feng, Jamie
    Aredo, Jacqueline V.
    Parikh, Kaushal
    Harris, Jeremy Phillip
    Manana, Ana I. Velazquez
    Ragavan, Meera Vimala
    Lin, Jessica Jiyeong
    Piotrowska, Zofia
    Fitzgerald, Bailey Gleason
    Grohe, Christian
    Sankar, Kamya
    Neal, Joel W.
    Wakelee, Heather A.
    Shepherd, Frances A.
    Herbst, Roy S.
    Naqash, Abdul Rafeh
    Goldberg, Sarah B.
    Kim, So Yeon
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [42] Real-World Outcomes of Stage III NSCLC Treated with Chemoradiation plus /- durvalumab
    Duan, R.
    Kordon, A.
    Kwan, M.
    Yadav, P.
    Thomas, T. O.
    Abazeed, M.
    Gharzai, L. A.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2024, 118 (01): : E11 - E11
  • [43] Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC
    Antonia, S. J.
    Villegas, A.
    Daniel, D.
    Vicente, D.
    Murakami, S.
    Hui, R.
    Kurata, T.
    Chiappori, A.
    Lee, K. H.
    de Wit, M.
    Cho, B. C.
    Bourhaba, M.
    Quantin, X.
    Tokito, T.
    Mekhail, T.
    Planchard, D.
    Kim, Y. -C.
    Karapetis, C. S.
    Hiret, S.
    Ostoros, G.
    Kubota, K.
    Gray, J. E.
    Paz-Ares, L.
    Carpeno, J. de Castro
    Faivre-Finn, C.
    Reck, M.
    Vansteenkiste, J.
    Spigel, D. R.
    Wadsworth, C.
    Melillo, G.
    Taboada, M.
    Dennis, P. A.
    Ozguroglu, M.
    NEW ENGLAND JOURNAL OF MEDICINE, 2018, 379 (24): : 2342 - 2350
  • [44] Robust and Long-lasting Efficacy of Durvalumab Consolidation in Stage III NSCLC after Induction Chemotherapy and definitive Chemoradiation: Focus on Treatment Choice and prognostic Factors
    Guberina, M.
    Poettgen, C.
    Guberina, N.
    Gauler, T.
    Metzenmacher, M.
    Wiesweg, M.
    Richlitzki, C.
    Ploenes, T.
    Forsting, M.
    Wetter, A.
    Herrmann, K.
    Hautzel, H.
    Darwiche, K.
    Theegarten, D.
    Aigner, C.
    Schuler, M.
    Eberhardt, W. E. E.
    Stuschke, M.
    STRAHLENTHERAPIE UND ONKOLOGIE, 2022, 198 (SUPPL 1) : S15 - S15
  • [45] Radiographic patterns of progression in patients with EGFR-mutant NSCLC undergoing EGFR TKI therapy.
    Brenner, Nicole
    Bastos, Bruno R.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [46] Factors associated with failure to start consolidation durvalumab after definitive chemoradiation for locally advanced NSCLC
    Langberg, Christian Wilhelm
    Horndalsveen, Henrik
    Helland, Aslaug
    Haakensen, Vilde Drageset
    FRONTIERS IN ONCOLOGY, 2023, 13
  • [47] Outcomes After Combined Modality Therapy for EGFR-Mutant and Wild-Type Locally Advanced NSCLC
    Mak, Raymond H.
    Doran, Elizabeth
    Muzikansky, Alona
    Kang, Josephine
    Neal, Joel W.
    Baldini, Elizabeth H.
    Choi, Noah C.
    Willers, Henning
    Jackman, David M.
    Sequist, Lecia V.
    ONCOLOGIST, 2011, 16 (06): : 886 - 895
  • [48] Real-World Experience (RWE) of Consolidation Durvalumab After Concurrent Chemoradiotherapy (CCRT) In Stage III NSCLC
    Huang, Y.
    Zhao, J.
    Soon, Y. Y.
    Wong, A.
    Ang, Y.
    Asokumaran, Y.
    Low, J. L.
    Lee, M.
    Choo, J.
    Chan, G.
    Kee, A.
    Tay, S. H.
    Goh, B. C.
    Soo, R.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (10) : S1044 - S1044
  • [49] Outcomes of Durvalumab Consolidation Treatment in Stage III Unresectable NSCLC: A Retrospective RealWorld Study
    Ljubicic, L.
    Bitar, L.
    Seiwerth, F.
    Bacelic-Gabelica, A.
    Srdic, D.
    Badovinac, S.
    Plestina, S.
    Korsic, M.
    Pavic, T.
    Samarzija, M.
    Jakopovic, M.
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (10) : S586 - S586
  • [50] A cost-effectiveness analysis of consolidation immunotherapy with durvalumab in stage III NSCLC.
    Panje, C.
    Lupatsch, J. E.
    Barbier, M.
    Pardo, E.
    Lorez, M.
    Dedes, K. J.
    Aebersold, D. M.
    Plasswilm, L.
    Gautschi, O.
    Schwenkglenks, M.
    RADIOTHERAPY AND ONCOLOGY, 2020, 152 : S540 - S540
12345